CENTRAL LIBRARY

Welcome to Online Public Access Catalogue (OPAC)

Normal view MARC view ISBD view

Therapeutic proteins : strategies to modulate their plasma half-lives / edited by Roland Kontermann.

Contributor(s): Kontermann, Roland, 1961- [editor.].
Material type: materialTypeLabelBookPublisher: Weinheim, Germany : Wiley-Blackwell, an imprint of John Wiley & Sons, 2012Copyright date: ©2012Description: 1 online resource (374 pages) : illustrations (some color).Content type: text Media type: computer Carrier type: online resourceISBN: 9783527644827; 3527644822; 9783527644797; 3527644792; 9783527644780; 3527644784; 9783527644803; 3527644806; 128345422X; 9781283454223.Subject(s): Protein drugs -- Design | Proteins -- Therapeutic use | Proteins -- pharmacokinetics | Half-Life | MEDICAL -- Pharmacology | Protein drugs -- Design | Proteins -- Therapeutic useGenre/Form: Electronic books.Additional physical formats: Print version:: Therapeutic proteins.DDC classification: 615.3 Online resources: Wiley Online Library
Contents:
General information -- Half-life modulating strategies : an introduction -- Pharmacokinetics and half-life of protein therapeutics -- Half-life extension through chemical and post-translational modifications -- Half-life extension through PEGylation -- Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics -- Half-life extension through O-glycosylation -- Polysialic acid and polysialylation to modulate antibody pharmacokinetics -- Half-life extension through HESylation -- Half-life modulation involving recycling by the neonatal Fc receptor -- The biology of the neonatal Fc receptor (FcRn) -- half-life extension by fusion to the Fc region -- Monomeric Fc fusion technology: an approach to create long-lasting clotting factors -- The diverse roles of FcRn: implications for antibody engineering -- Half-life extension by fusion to recombinant albumin -- AlbudAb technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives -- Half-life extension by binding to albumin through an albumin binding domain -- Half-life extension by binding to albumin through small molecules -- Half-life extension with pharmaceutical formulations -- Half-life extension with pharmaceutical formulations: liposomes -- Half-life extension with pharmaceutical formulations: nanoparticles by the miniemulsion process.
Summary: For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals.
Tags from this library: No tags from this library for this title. Log in to add tags.
No physical items for this record

Includes bibliographical references and index.

General information -- Half-life modulating strategies : an introduction -- Pharmacokinetics and half-life of protein therapeutics -- Half-life extension through chemical and post-translational modifications -- Half-life extension through PEGylation -- Half-life extension of therapeutic proteins via genetic fusion to recombinant PEG mimetics -- Half-life extension through O-glycosylation -- Polysialic acid and polysialylation to modulate antibody pharmacokinetics -- Half-life extension through HESylation -- Half-life modulation involving recycling by the neonatal Fc receptor -- The biology of the neonatal Fc receptor (FcRn) -- half-life extension by fusion to the Fc region -- Monomeric Fc fusion technology: an approach to create long-lasting clotting factors -- The diverse roles of FcRn: implications for antibody engineering -- Half-life extension by fusion to recombinant albumin -- AlbudAb technology platform: versatile albumin binding domains for the development of therapeutics with tunable half-lives -- Half-life extension by binding to albumin through an albumin binding domain -- Half-life extension by binding to albumin through small molecules -- Half-life extension with pharmaceutical formulations -- Half-life extension with pharmaceutical formulations: liposomes -- Half-life extension with pharmaceutical formulations: nanoparticles by the miniemulsion process.

Online resource; title from resource home page (ebrary, viewed on June 17, 2014).

For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals.

There are no comments for this item.

Log in to your account to post a comment.

Khulna University of Engineering & Technology

Funded by: HEQEP, UGC, Bangladesh